Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.43 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.43 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL139043 | 0.95 | LMNA (0.59) | LMNACES2CES1MEN1KMT2A | |
| Bicarbonate SCHEMBL2779583 | 0.94 | LMNA (0.58) | LMNACES2CES1MEN1KMT2A | |
| Carbamic Acid SCHEMBL1695357 | 0.88 | CES2 (0.54) | LMNACES2CES1MEN1KMT2A | |
| SCHEMBL6203480 | 0.83 | CES2 (0.61) | LMNACES2CES1MEN1KMT2A | |
| SCHEMBL2337735 | 0.83 | MEN1 (0.43) | LMNACES2CES1MEN1KMT2A | |
| SCHEMBL139044 | 0.83 | CES2 (0.59) | LMNACES2CES1MEN1KMT2A | |
| Carbamic Acid SCHEMBL4383137 | 0.82 | PARP1 (0.58) | LMNACES2CES1GPR139PARP1 | |
| SCHEMBL14181968 | 0.82 | CES2 (0.48) | CES2CES1MEN1KMT2AKDM4E | |
| Carbamic Acid SCHEMBL23407287 | 0.82 | CA1 (0.50) | LMNACES2CES1MEN1KMT2A | |
| Bicarbonate SCHEMBL291493 | 0.81 | CES2 (0.58) | LMNACES2CES1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250196456-A1 | METHOD FOR THE MANUFACTURING OF AN OPTICAL ELEMENT, OPTICAL ELEMENT THUS OBTAINED | ESSILOR INTERNATIONAL (FR) | 2025-06-19 | — | — | US | disclosed |
| US-12263655-B2 | Method for the manufacturing of an optical element, optical element thus obtained | ESSILOR INTERNATIONAL (FR) | 2025-04-01 | — | — | US | disclosed |
| US-12215100-B2 | Anticancer compounds | PHARMA MAR, S.A. (ES) | 2025-02-04 | — | — | US | disclosed |
| EP-3898613-B1 | ANTICANCER COMPOUNDS | PHARMA MAR SA (ES) | 2023-08-09 | — | — | EP | disclosed |
| CN-112789161-B | Method for manufacturing an optical element and optical element obtained thereby | 依视路国际公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-3860838-B1 | METHOD FOR THE MANUFACTURING OF AN OPTICAL ELEMENT, OPTICAL ELEMENT THUS OBTAINED | ESSILOR INT (FR) | 2022-06-22 | — | — | EP | disclosed |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | PHARMA MAR, S.A. (ES) | 2022-02-24 | — | — | US | disclosed |
| US-20210379846-A1 | METHOD FOR THE MANUFACTURING OF AN OPTICAL ELEMENT, OPTICAL ELEMENT THUS OBTAINED | ESSILOR INTERNATIONAL (FR) | 2021-12-09 | — | — | US | disclosed |
| EP-3898613-A1 | ANTICANCER COMPOUNDS | Pharma Mar S.A. (ES) | 2021-10-27 | — | — | EP | disclosed |
| EP-3860838-A1 | METHOD FOR THE MANUFACTURING OF AN OPTICAL ELEMENT, OPTICAL ELEMENT THUS OBTAINED | ESSILOR INTERNATIONAL (FR) | 2021-08-11 | — | — | EP | disclosed |
| WO-2014170295-A1 | COMPOUNDS POTENTIATING THE ACTIVITY OF ANTIFUNGAL DRUGS | FUNDACIÓN MEDINA. CENTRO DE EXCELENCIA EN INVESTIGACIÓN DE MEDICAMENTOS INNOVADORES EN ANDALUCÍA (ES) | 2014-10-23 | — | — | WO | disclosed |
| EP-2792683-A1 | Compounds potentiating the activity of antifungal drugs | Fundacion MEDINA. Centro de Excelencia en Investigacion de Medicamentos Innovadores en Andalucia (ES) | 2014-10-22 | — | — | EP | disclosed |
| US-8748388-B2 | Antitumoral compounds | PHARMA MAR, S.A. (ES) | 2014-06-10 | — | — | US | disclosed |
| EP-2576569-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | Pharma Mar S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | PHARMA MAR, S.A. (ES) | 2013-03-14 | — | — | US | disclosed |
| EP-2231695-B1 | ANTITUMORAL COMPOUNDS | PHARMA MAR SA (ES) | 2013-02-13 | — | — | EP | disclosed |
| WO-2011147828-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF ECTEINASCIDIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2011-08-25 | — | — | US | disclosed |
| WO-2010149688-A2 | ANTITUMORAL COMPOUNDS | PHARMA MAR, S.A. (ES) | 2010-12-29 | — | — | WO | disclosed |
| US-20100292163-A1 | Antitumoral Compounds | PHARMA MAR, S.A. (ES) | 2010-11-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130066067-A1 | Synthetic Process for the Manufacture of Ecteinascidin Compounds | SERPINH1, ERLIN2, PTMA | LMNA 930/4885CES2 1551/4885CES1 2936/4885 |
| US-20110207674-A2 | ANTITUMORAL COMPOUNDS | TP53, XPO1, TOP2B | LMNA 3075/4885CES2 2449/4885CES1 1265/4885 |
| US-20100292163-A1 | Antitumoral Compounds | TP53, XPO1, TOP2B | LMNA 3075/4885CES2 2449/4885CES1 1265/4885 |
| US-20220056021-A1 | ANTICANCER COMPOUNDS | TP53, MCL1, MYC | LMNA 1756/4885CES2 3537/4885CES1 3249/4885 |
| US-12215100-B2 | Anticancer compounds | TP53, MCL1, MYC | LMNA 1757/4885CES2 3538/4885CES1 3251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.